BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 8, 2026
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

Australian government makes VC pot sweeter for biotech investments

Oct. 12, 2016
By Tamra Sami
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country.
Read More

Australian Government makes VC pot sweeter for lifescience investments

Oct. 6, 2016
By Tamra Sami

Australian government makes VC pot sweeter for biotech investments

Oct. 6, 2016
By Tamra Sami
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country.
Read More

Proposed R&D tax incentive could hurt Australia’s small firms

Oct. 5, 2016
By Tamra Sami
PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country.
Read More

Australia's R&D tax incentive could hurt small med-tech and biotech companies

Oct. 3, 2016
By Tamra Sami

Proposed R&D tax incentive could hurt Australia’s small firms

Oct. 3, 2016
By Tamra Sami
PERTH, Australia – The Australian government’s release of the Review of the R&D Tax Incentive met a mixed response from the biopharma and med-tech communities operating in the country.
Read More

Australia gears up to reform drug, device regulations, speed access to therapies

Sep. 21, 2016
By Tamra Sami
PERTH, Australia – The pharma and medical device industry praised the Australian government on new reforms announced late last week that increase the pathways for marketing approval for drugs and devices and reduce regulatory red tape and redundancies.
Read More

Australia gears up to reform drug, device regulations, speed access to therapies

Sep. 19, 2016
By Tamra Sami

Australia gears up to reform drug, device regulations, speed access to therapies

Sep. 19, 2016
By Tamra Sami
PERTH, Australia – The pharma and medical device industry praised the Australian government on new reforms announced late last week that increase the pathways for marketing approval for drugs and devices and reduce regulatory red tape and redundancies.
Read More

TGA's drug labeling overhaul aimed to align Australia requirements

Aug. 24, 2016
By Tamra Sami
PERTH, Australia – Drug manufacturers with operations in Australia will have four years to transition to new labeling requirements for medicines in Australia, long-awaited changes that may align with 21st century practices but, industry argued, likely won't solve the entire problem of medication errors.
Read More
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 8, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • CAR T cell attacking cancer cells

    Development and characterization of anti-CD19 in vivo CAR T therapy

    BioWorld Science
    Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing